About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5795840
Allelic
Composition
Aldh1b1tm1.1(KOMP)Vlcg/Aldh1b1tm1.1(KOMP)Vlcg
Genetic
Background
involves: C57BL/6J * C57BL/6NTac * CBA
Cell Lines 11807A-E11
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Aldh1b1tm1.1(KOMP)Vlcg mutation (0 available); any Aldh1b1 mutation (35 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• at 6 weeks of age, islets exhibit increased levels of apoptosis, as shown by double immunofluorescence for caspase-3 and either insulin or glucagon
• TUNEL staining indicated increased levels of apoptosis in all islets by 52 weeks of age
• at 6 weeks of age, islets exhibit increased levels of apoptosis, as shown by double immunofluorescence for caspase-3 and insulin
• at 8 weeks of age, expression of several cell cycle and mitosis-associated genes is altered, consistent with increased mitosis rates
• at 6 weeks of age, mice show defects and heterogeneity in islet patterning
• PH3 immunofluorescence indicated that mitotic activity is 2-fold higher at P1 and 50-fold higher at 6 weeks of age
• phosphorylated AMPKA levels are significantly increased suggesting that beta cells are energy depleted
• ATP levels are reduced by ~2-fold in isolated islets relative to control islets
• at 6 weeks of age, many islets contain supernumerary glucagon-positive (GCG+) cells
• continued mitosis in islets results in a 3.6-fold expansion of the beta cell mass by 20 weeks of age
• however, beta cell mass differences are negligible at P1 and 6 weeks of age
• at 6 weeks of age, many islets contain supernumerary somatostatin-positive (SOM+) cells
• continued mitosis results in a 2-fold increase in median islet size by 20 weeks of age
• although early pancreas development is normal, progenitor differentiation is accelerated during the secondary transition, indicating premature lineage commitment
• the number of neurogenin 3-positive (NGN3+) endocrine progenitors is transiently increased at E13.5 and E14.5
• the number of C-peptide-positive (C-PEP+) cells, but not glucagon-positive (GCG+) cells, is increased at E14.5
• amylase complex-positive (AMY+) acinar cells and duct Dolichos biflorus agglutinin-positive (DBA+) cells appear earlier and are more numerous at E14.5 relative to wild-type controls
• the number of epithelial cells in mitosis (Phosphohistone-H3+/E-cadherin+ cells) is transiently increased at E14.5
• however, apoptosis levels remain very low and similar to those in wild-type controls
• transcriptome analyses of P1 islets revealed impaired islet patterning with misregulation of key beta cell transcription factors and genes critical for beta cell function
• defects and heterogeneity in islet patterning persist into adulthood, with the number of misregulated genes expanding >6-fold at 8 weeks of age
• at 8 weeks of age, affected beta cells contain 30% fewer type 1 (mature) secretory granules and 22% more type 2 (immature) granules than wild-type cells
• z score heat maps showed misregulated expression of several genes involved in secretory granule formation and exocytosis
• 2.6-fold increase in glucagon content in the pancreas at 8 weeks of age
• pancreas glucagon levels are increased at 52 weeks of age
• at 8 weeks of age, acute insulin secretion during IPGTT is impaired; first-phase response takes ~3 times as long to peak without reaching control levels while second-phase response is absent
• acute insulin secretion is weak by 20 weeks and monophasic at 52 weeks of age
• at 20 weeks of age, glucose-stimulated insulin secretion is reduced by 13-fold in isolated islets relative to control islets
• following stimulation with tolbutamide (a K+ channel antagonist) or BayK8644 (a specific L-type voltage-sensitive Ca2+ channel agonist), insulin release is reduced by 5-fold in isolated islets relative to control islets, indicating impaired stimulus-coupling secretion
• transient increase in insulin and proinsulin content in the pancreas at 8 weeks of age
• however, insulin-to-proinsulin ratio remains similar to that in controls until 20 weeks of age

homeostasis/metabolism
N
• at 20 weeks of age, mice show normal hepatic stores of glycogen, expression of liver G6Pase, and gluconeogenesis rates relative to controls
• 2.6-fold increase in glucagon content in the pancreas at 8 weeks of age
• pancreas glucagon levels are increased at 52 weeks of age
• at 8 weeks of age, acute insulin secretion during IPGTT is impaired; first-phase response takes ~3 times as long to peak without reaching control levels while second-phase response is absent
• acute insulin secretion is weak by 20 weeks and monophasic at 52 weeks of age
• at 20 weeks of age, glucose-stimulated insulin secretion is reduced by 13-fold in isolated islets relative to control islets
• following stimulation with tolbutamide (a K+ channel antagonist) or BayK8644 (a specific L-type voltage-sensitive Ca2+ channel agonist), insulin release is reduced by 5-fold in isolated islets relative to control islets, indicating impaired stimulus-coupling secretion
• transient increase in insulin and proinsulin content in the pancreas at 8 weeks of age
• however, insulin-to-proinsulin ratio remains similar to that in controls until 20 weeks of age
• mice develop age-dependent hyperglycemia from 12 weeks onwards
• onset of hyperglycemia is preceded by reduced glucose tolerance and significant delay in acute insulin secretion
• at 8 weeks of age, mice show a significant delay in blood glucose clearance during intraperitoneal glucose tolerance testing (IPGTT)
• glucose tolerance is further reduced by 20 weeks and deteriorated by 52 weeks of age
• at 52 weeks of age, mice show clear signs of insulin resistance during intraperitoneal insulin tolerance testing (IPITT)
• however, normal rates of glucose clearance are observed during IPITT at 8 and 20 weeks of age
• in response to glucose stimulation, increase in intracellular Ca2+ concentration is reduced in islets isolated from 20-week-old mice relative to control islets, due to a subset islets (14 of 59) with very low or negligible response

cellular
• at 6 weeks of age, islets exhibit increased levels of apoptosis, as shown by double immunofluorescence for caspase-3 and either insulin or glucagon
• TUNEL staining indicated increased levels of apoptosis in all islets by 52 weeks of age
• at 6 weeks of age, islets exhibit increased levels of apoptosis, as shown by double immunofluorescence for caspase-3 and insulin
• transcriptome analyses of P1 islets revealed impaired islet patterning with misregulation of key beta cell transcription factors and genes critical for beta cell function
• defects and heterogeneity in islet patterning persist into adulthood, with the number of misregulated genes expanding >6-fold at 8 weeks of age
• at 8 weeks of age, affected beta cells contain 30% fewer type 1 (mature) secretory granules and 22% more type 2 (immature) granules than wild-type cells
• z score heat maps showed misregulated expression of several genes involved in secretory granule formation and exocytosis
• at 8 weeks of age, expression of several cell cycle and mitosis-associated genes is altered, consistent with increased mitosis rates
• pancreatic islets fail to show induction of several genes involved in protection from and repair of oxidative damage from P1 to adulthood
• at 20 weeks of age, islets show high ROS content and markedly increased oxidation of unsaturated fatty acids, indicating oxidative stress


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
10/22/2024
MGI 6.24
The Jackson Laboratory